We hope to see you again soon!
You are now leaving Lundbeck UK's website (www.lundbeck.com/uk) for an external website. External links are provided as a resource to the viewer. Lundbeck UK are not responsible for the external website and its content.
UK-NOTPR-1010 | April 2022
Products
Names and Compounds of our Products
Report An Adverse Event:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.
Adverse events should also be reported to Lundbeck Limited, Medical Information on 01908 638972 or at SafetyLuUnitedKingdom@lundbeck.com.
Lundbeck Ltd UK Distributed or Promoted Products, February 2022
All our products are prescription-only medicines (POM). If more information is required, please refer to the local Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) using the links below.
Abilify® (aripiprazole)* *Abilify® is marketed jointly with Otsuka who are the Marketing Authorisation (MA) holder Click here for the Abilify 5mg tablets SPC Click here for the Abilify 10mg tablets SPC Click here for the Abilify 15mg tablets SPC Click here for the Abilify tablets 30mg SPC Click here for the Abilify tablets PIL Click here for the Abilify oral solution SPC Click here for the Abilify oral solution PIL |
Abilify Maintena® (aripiprazole)*
Presentations: *Abilify Maintena® is marketed jointly with Otsuka who are the MA holder.
SPC & PIL Links: |
Brintellix® (vortioxetine)
SPC & PIL Links: Click here for the Brintellix tablets SPC Click here for the Brintellix tablets PIL |
Cipralex® (escitalopram)
SPC & PIL Links: Click here for the Cipralex tablets SPC Click here for the Cipralex tablets PIL |
Cipramil® (citalopram)
Presentations:
SPC & PIL Links: Click her for the Cipramil tablets SPC Click here for the Cipramil tablets PIL |
Clopixol® (zuclopenthixol)
Presentations:
SPC & PIL Links: Click here for the Clopixol tablets SPC Click here for the Clopixol tablets PIL Click here for the Clopixol injections SPC |
Clopixol Acuphase® (zuclopenthixol acetate)
SPC & PIL Links: |
Depixol® (flupentixol)
Presentations: Depixol® contains the active substance flupentixol. |
Ebixa® (memantine)
Presentations: Ebixa® contains the active substance memantine. Click here for the Ebixa 10mg tablets SPC Click here for the Ebixa 10mg tablets PIL Click here for Ebixa 20mg tablets SPC Click here for the Ebixa 20mg tablets PIL Click here for the Ebixa 10mg tablets SPC (NI) Click here for the Ebixa 10mg tablets PIL (NI) Click here for the Ebixa 20mg tablets SPC (NI) Click here for the Ebixa 20mg tablets PIL (NI) Click here for the Ebixa tablets, treatment initiation pack SPC Click here for the Ebixa tablets, treatment initiation pack SPC (NI) Click here for the Ebixa tablets treatment initiation PIL Click here for the Ebixa tablets treatment initiation PIL (NI) |
Product: Fluanxol® (flupentixol)
Presentations: Fluanxol® contains the active substance flupentixol.
SPC & PIL Links: |
Selincro® (nalmefene) Selincro® contains the active substance nalmefene. It is available as tablets.
SPC & PIL Links: |
More from lundbeck
R&D of new and improved treatments is at the core of what we do.
We see patients as people and are committed to support the person behind.
Discover our projects and compounds in development.
UK-NOTPR-0541 | April 2022